Inscripta Adds $20M To Series C Funding
Boulder-based gene editing technology developer Inscripta has added another $20M in funding to its Series C round, the company said this week, bringing the round to a total of $105.5M. According to Inscripta, the new funding came from its existing investors, including Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. The company had originally announced its Series C in 2018, worth $85.5M. According to the company, the new funds will help it ramp its commercialization efforts. Inscripta, led by CEO Kevin Ness, develops software, equipment, and the technology for "single cell engineering", including a family of CRISPR enzymes used for gene editing by scientists. Ness was the co-founder of uantaLife and 10x Genomics; the company's chairman is Illumina co-founder and former Ceo John Stuelpnagel.
posted on Friday, April 5, 2019
Related companies:
Inscripta
Related stories:
> Inscripta Finds $55.5M For Gene Editing Tools
> GlobeImmune Adds To Series B
> Enerpulse Adds $5M To Series B Round
> Havenly Adds $5.8M To Series A
> Medivance Adds $23M
Techrockies.com Home